Abstract: Objective To observe the therapeutic effects of Qinghua Liangxue Huayu decoction on patients with
HBV-related acute-on-chronic (subacute) liver failure. Methods Total of 74 patients with HBV-related acute-on-
chronic (subacute) liver failure were randomly divided into treatment group and control group, 37 cases in each
group. Both groups were given basic therapy plus symptomatic and supportive treatment. Patients in treatment
group were also given the Qinghua Liangxue Huayu decoction treatment. The treatment course was 8 weeks. The
therapeutic effect was evaluated before the treatment, and in the 1st, 2nd, 4th, 6th and 8th week. The mortality
rate, laboratory indexes (ALT, AST, TBil, DBil, ALB, PTA) and MELD scores were observed before and after
treatment for 1, 2, 4, 6 and 8 weeks. Results After treating for 8 weeks, the survial rate in the treatment group
(89.19%) was significantly higher than that in control group (70.27%, P = 0.043). Compared with control group,
the level of TBil and DBil in treatment group reduced significantly after treating for 4, 6 and 8 weeks (P ＜ 0.05).
After treating for 4 weeks, the MELD scores had statistical difference between the two groups (P = 0.025) The
TCM syndrome score of the two groups had statistical difference from the second week (P ＜ 0.05). Conclusion
Qinghua Liangxue Huayu decoction combined with western medicine is effective for HBV-related acute-on-
chronic (subacute) liver failure with a low mortality rate and better efficacy.